Clinical trial results published for Cold Atmospheric Plasma treating Actinic Keratoses

By: Adtec Europe Ltd
 
 
Spread the Word
Listed Under

Tag:
Clinical Trial

Industry:
Medical

Location:
London City - London, Greater - England

LONDON - June 26, 2020 - PRLog -- Adtec Healthcare celebrates a new clinical trial publication released from the University Essen Hospital in Germany. Professor Alexander Rösch and his team at the Department of Dermatology have successfully completed their clinical trial, "Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized, and rater-blinded study (ACTICAP)". A link to the publication can be found at JEADV here: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16735 (https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16735?fbclid=IwAR2NgUUvnC_DqBnnNUbiXJJQP_LVW7HIHJhaNxHY7-ruGvRxS1K7FbHzZCM)

Actinic keratoses (AK) represent the most common skin malignancy worldwide and are considered the earliest stage in cutaneous squamous cell carcinoma development. Conventional therapies bear significant side effects and/or are limited to small treatment areas. Thus, there is a continuing need for nontoxic lesion- and field-directed treatment options for extensive AK. Cold atmospheric plasma (CAP) is a partially ionized gas containing a mixture of reactive oxygen and nitrogen species. In addition to its well documented antimicrobial properties, growing evidence points to antitumor effects.

The clinical trial tests the difference in clinical efficacy of our Adtec SteriPlas medical device vs Diclofenac 3% gel for the treatment of actinic keratoses lesions in a total of 60 patients, aged between 56-91 years of age.

Cold atmospheric plasma treatment with the Adtec SteriPlas showed significantly better effectiveness over diclofenac in reducing the actinic keratoses lesion count. Unlike Diclofenac, cold atmospheric plasma showed no major side effects during the study. Thus, this modality might be especially well-suited for patients who require nontoxic treatment options, particularly immunocompromised patients and those with extensive field cancerization. This continues to be one of our strongest and most favoured characteristics of the Adtec SteriPlas: no side effects.

We encourage you to read the clinical trial publication and welcome any questions that you have.

Contact
Adtec Healthcare
***@adtec.eu.com
End
Email:***@adtec.eu.com Email Verified
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Adtec Healthcare PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share